Market closed
Immunic/$IMUX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Immunic
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
Ticker
$IMUX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
85
Website
Immunic Metrics
BasicAdvanced
$109M
Market cap
-
P/E ratio
-$1.12
EPS
1.88
Beta
-
Dividend rate
Price and volume
Market cap
$109M
Beta
1.88
52-week high
$1.84
52-week low
$0.97
Average daily volume
864K
Financial strength
Current ratio
2.709
Quick ratio
2.564
Long term debt to equity
0.451
Total debt to equity
0.451
Management effectiveness
Return on assets (TTM)
-90.90%
Return on equity (TTM)
-216.24%
Valuation
Price to book
2.64
Price to tangible book (TTM)
2.64
Price to free cash flow (TTM)
-1.367
Growth
Earnings per share change (TTM)
-62.58%
3-year earnings per share growth (CAGR)
-33.83%
What the Analysts think about Immunic
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Immunic stock.
Immunic Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Immunic Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Immunic News
AllArticlesVideos
Immunic's IMU-856 shows potential in gastrointestinal health trials - ICYMI
Proactive Investors·4 weeks ago
Immunic reports positive Phase 1 results for celiac disease therapy published in The Lancet
Proactive Investors·4 weeks ago
Immunic, Inc. (IMUX) Q3 2024 Earnings Call Transcript
Seeking Alpha·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Immunic stock?
Immunic (IMUX) has a market cap of $109M as of December 13, 2024.
What is the P/E ratio for Immunic stock?
The price to earnings (P/E) ratio for Immunic (IMUX) stock is 0 as of December 13, 2024.
Does Immunic stock pay dividends?
No, Immunic (IMUX) stock does not pay dividends to its shareholders as of December 13, 2024.
When is the next Immunic dividend payment date?
Immunic (IMUX) stock does not pay dividends to its shareholders.
What is the beta indicator for Immunic?
Immunic (IMUX) has a beta rating of 1.88. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.